ClinicalTrials.gg
CompletedNCT00903448Updated Dec 31, 2010Results posted

Comparison of Prilosec Over-the-counter (OTC)® Versus Prevacid® for Gastric Acid Suppression

A Phase 4 interventional study of Prilosec OTC (omeprazole-magnesium) and Prevacid in Healthy, sponsored by Procter and Gamble. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2010-12-31.

Sponsored by Procter and Gamble · Phase 4, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The objective of this study is to compare Prilosec OTC® to Prevacid® for gastric acid suppression.

02

Conditions studied

  • Healthy

Keywords

  • Normal Healthy Subject Population
03

In context

Lead sponsor

Procter and Gamble is the lead sponsor of 83 studies on the registry; none are open to participants now.

Of its 10 completed or terminated interventional studies of FDA-regulated products, 10 (100%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • normal subjects who are age 18-65
  • generally healthy
  • non- females or those using

Exclusion criteria

Exclusion Criteria:

  • history of significant GI disease
  • any significant medical illness
  • history of , allergy or intolerance to omeprazole, lansoprazole or other proton pump inhibitors
  • currently using GI medications
  • GI disorder or surgery leading to impaired drug absorption
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 4
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    A

    Prilosec OTC

    Drug: Prilosec OTC (omeprazole-magnesium)

  • Active comparator
    B

    Prevacid

    Drug: Prevacid

Interventions

  • Prilosec OTC (omeprazole-magnesium 20.6 mg) tablet to be taken with a glass of water prior to breakfast

  • Prevacid (15 mg lansoprazole) capsule to be taken with a glass of water prior to breakfast

06

What researchers measure

Primary outcomes

  1. Mean Percent Time That Gastric pH > 4.0 on Day 5

    for 24 hours starting Day 5 for each period

    Time frame: 24 hours

07

Results

Posted Nov 22, 2010

Participant flow

This single-center, double-blind, randomized, 2-treatment, 3-period cross-over study conducted in forty healthy adult subjects living in the vicinity of the site.

Period 1: 5 Days Then 10 Day Washout
Participant flow — Period 1: 5 Days Then 10 Day Washout
MilestonePrilosec OTC Then Prevacid Then PrevacidPrevacid Then Prilosec OTC Then Prilosec OTC
Started2020
Completed2020
Not completed00
Period 2: 5 Days Then 10 Day Washout
Participant flow — Period 2: 5 Days Then 10 Day Washout
MilestonePrilosec OTC Then Prevacid Then PrevacidPrevacid Then Prilosec OTC Then Prilosec OTC
Started2020
Completed2020
Not completed00
Period 3: 5 Days
Participant flow — Period 3: 5 Days
MilestonePrilosec OTC Then Prevacid Then PrevacidPrevacid Then Prilosec OTC Then Prilosec OTC
Started2020
Completed2020
Not completed00

Outcome measures

PrimaryMean Percent Time That Gastric pH > 4.0 on Day 5

for 24 hours starting Day 5 for each period

Time frame:
24 hours
Reported as:
Mean · percent time gastric pH exceeds 4.0
Mean Percent Time That Gastric pH > 4.0 on Day 5
percent time gastric pH exceeds 4.0Prilosec OTC Then Prevacid Then PrevacidPrevacid Then Prilosec OTC Then Prilosec OTC
Mean Percent Time That Gastric pH > 4.0 on Day 536.8 ± 3.4545.7 ± 3.45
Statistical analysis
  • Prilosec OTC Then Prevacid Then Prevacid vs Prevacid Then Prilosec OTC Then Prilosec OTC · Mixed Models Analysis · p = < 0.0001 (The least squares treatment means, i.e. adjusted treatment means, and standard errors were computed from the analysis of variance models.) · Mean difference (final values): 8.9

Adverse events

Non-serious events are listed at a 1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Prilosec OTC Then Prevacid Then Prevacid—0/40 (0%)1/40 (2.5%)
Prevacid Then Prilosec OTC Then Prilosec OTC—0/40 (0%)2/40 (5%)
Most frequent other events
Most frequent other events
EventPrilosec OTC Then Prevacid Then PrevacidPrevacid Then Prilosec OTC Then Prilosec OTC
DiarrheaGastrointestinal disorders0/402/40
HeadacheNervous system disorders0/401/40
Skin DiseaseSkin and subcutaneous tissue disorders1/400/40

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Entire Study Population
<=18 years0
Between 18 and 65 years40
>=65 years0
Age Continuous
Age Continuous(years)Entire Study Population
Mean28 ± 6.65
Sex: Female, Male
Sex: Female, Male(Participants)Entire Study Population
Female12
Male28
Region of Enrollment
Region of Enrollment(participants)Entire Study Population
United States40
08

Study locations

1 site
  • Research Site
    Oklahoma City, Oklahoma 73104, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2009, a primary completion of Jun 2009 and a completion of Jun 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2010, 1 year 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 14, 2009
First posted
May 18, 2009
Start
Apr 2009
Primary completionActual
Jun 2009
CompletionActual
Jun 2009
Results first posted
Nov 22, 2010
Last update
Dec 31, 2010
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 31, 2010, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00903448
Lead sponsor
Procter and Gamble
First posted
May 18, 2009
Start date
Apr 2009
Primary completion
Jun 2009
Completion
Jun 2009
Results posted
Nov 22, 2010
Last update
Dec 31, 2010

Study contacts

Simon H Magowan, MD
study director · Procter and Gamble

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Omeprazole

Start the discussion